Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Sirolimus. Found 9 abstracts

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2015 Nov 05;373(19):1803-13.
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44.   PMCID: Pmc4229637
Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. The oncologist. 2014 Apr;19(4):354-5.   PMCID: Pmc3983829
Figlin RA, Brown E, Armstrong AJ, Akerley W, Benson AB, Burstein HJ, Ettinger DS, Febbo PG, Fury MG, Hudes GR, Kies MS, Kwak EL, Morgan RJ, Mortimer J, Reckamp K, Venook AP, Worden F, Yen Y. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep;6 Suppl 5:S1-S20; quiz S21-S22.
Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR is activated in the majority of malignant melanomas. The Journal of investigative dermatology. 2008 Apr;128(4):980-7.
Yeager N, Brewer C, Cai KQ, Xu XX, Di Cristofano A. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. Cancer Res. 2008 Jan 15;68(2):444-9.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Karbowniczek M, Robertson GP, Henske EP. Rheb inhibits C-Raf activity and B-Raf/C-Raf heterodimerization. The Journal of biological chemistry. 2006 Jun 27;281(35):25447-56.
Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004 Jul 29;23(34):5853-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Sirolimus

Sirolimus metabolism Protein Kinase Inhibitors analogs & derivatives Protein Kinases Female pathology drug therapy therapeutic use Antineoplastic Combined Chemotherapy Protocols Signal Transduction Aged drug effects Phosphorylation Male Renal Cell Carcinoma Kidney Neoplasms Antineoplastic Agents Adult pharmacology Middle Aged 80 and over Aged EC 2-7-1-37 (Protein Kinases) Neoplasms Proto-Oncogene Proteins B-raf physiology chemistry TOR Serine-Threonine Kinases Prognosis 1-Phosphatidylinositol 3-Kinase dt [Drug Therapy] Cell Proliferation mortality 53123-88-9 (Sirolimus) Survival Analysis pa [Pathology] Monoclonal Antibodies genetics EC 2-7-1 (mTOR protein) adverse effects antagonists & inhibitors PTEN Phosphohydrolase Proto-Oncogene Proteins c-raf Randomized Controlled Trials as Topic Epithelium Drug Administration Schedule Transgenic Mice 0 (Protein Kinase Inhibitors) Monomeric GTP-Binding Proteins 0 (Morpholines) Treatment Outcome Protein Kinase C Cultured Cells Protein-Serine-Threonine Kinases Neuropeptides aa [Analogs & Derivatives] Dimerization US Gov't Support-PHS Phase III Clinical Trials as Topic Gene Expression Regulation 3-Ring Heterocyclic Compounds Cell Division mo [Mortality] ci [Chemically Induced] me [Metabolism] Thyroid Neoplasms Practice Guidelines as Topic Multiprotein Complexes Thyroid Gland Notch Receptors Nevus Human Cohort Studies Sulfones EC 2-7-1-37 (proto-oncogene protein akt) Adolescent Follicular Adenocarcinoma Cultured Tumor Cells DNA Mutational Analysis 0 (Interferon-alpha) Bryostatins Proto-Oncogene Proteins c-akt Apoptosis Ovarian Neoplasms Chromones pd [Pharmacology] Biological Tumor Markers de [Drug Effects] tu [Therapeutic Use] Proto-Oncogene Proteins antagonists & Ribosomal Protein S6 pharmacokinetics Serine Non-US Gov't Support EC 2-7-1-37 (Protein-Serine-Threonine Kinases) Hematologic Diseases Quality of Life Melanoma enzymology Morpholines 0 (Enzyme Inhibitors) Cisplatin inhibitors Interferon-alpha 0 (Proto-Oncogene Proteins) Proto-Oncogene Proteins p21(ras) 0 (Chromones) EC 2-7-1-137 (1-Phosphatidylinositol 3-Kinase) Cell Line 0 (Antineoplastic Agents) 15663-27-1 (Cisplatin) Neoplasm Staging Phase II Clinical Trials as Topic IGF Type 1 Receptor Skin Neoplasms Tertiary Protein Structure ae [Adverse Effects] Clinical Trials as Topic Mice Tissue Distribution tu [Therapeutic Use] Proportional Hazards Models Enzyme Inhibitors ai [Antagonists & Inhibitors] sc [Secondary] 0 (cci 779) Propionates Benzene Derivatives Young Adult Tumor Cell Line Sarcoma 154447-36-6 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) Follow-Up Studies
Last updated on Friday, August 14, 2020